University Home | Hospital | Pulse Employment | Contact Us | Search | News 
Thomas Jefferson University Search Jefferson
Jefferson Medical College Jefferson College of Graduate Studies Jefferson College of Health Professions
Menu

Thomas Jefferson University - Hallgeir Rui, M.D., Ph.D.
Hallgeir Rui, M.D., Ph.D.

Cancer Biology
Thomas Jefferson University
Jefferson Medical College
Kimmel Cancer Center
Department of Cancer Biology
Professor
Appointed: 2006
Mailing Address
233 S 10th St, BLSB 330
Philadelphia, Pennsylvania 19107
United States
Contact Information
Phone: 215-503-9259
Fax: 215-503-9246
Hallgeir.Rui@jefferson.edu
Personal Web Site
Qualifications
M.D. University of Oslo, Oslo, Norway, 1987
Ph.D. Pathology, University of Oslo, Norway 1988
Expertise and Research Interests
The Laboratory's current research is focused on mechanistic identification of aberrant Jak-Stat signal transduction during human breast cancer progression that the laboratory has discovered. Recent progress includes recognition of the prolactin-induced Jak2-Stat5 pathway as a pro-differentiation pathway in human breast cancer, which during progression of human breast cancer is replaced by aberrant signaling through a Jak1-Stat3 pathway that may promote invasion and metastasis. Consistent with this notion, new data demonstrate that activation of Stat5 is a highly favorable prognostic marker in node-negative breast cancer. An invasion-suppressive role of Stat5 in human breast cancer may explain the mechanism of the favorable prognosis associated with active Stat5 in early stage breast cancer. A new technology for microarraying of tissue, cells, and other solid materials, cutting edge matrix assembly (CEMA), has been developed.
Keywords
cancer; breast cancer; hormone; endocrinology; prolactin; growth hormone; estrogen; glucocorticoid; steroid hormones; Jak2; Stat5; Stat5a; Stat5b; immunohistochemistry; pathology; biomarker; early detection; microarray; tissue microarray; mouse modeling; EGFR; Her2; ErbB2; prolactin receptor;
Languages
English; Norwegian, Swedish; Danish; German
Publications
  • Rui H, Bjornland K, Skipenes G, Haugen K, Purvis K. Attitudes to death and terminal care in Norway [Holdnin­ger til doden og dodspleie i Norge]. Tidsskr Nor Laegefor 102: 1625-1629, 1982.

  • Rui H, Rui H, Gordeladze JO, Gautvik KM, Purvis K. Prolactin desensi­tizes the prostaglandin E1-dependent adenylyl cyclase of the rat prostate gland. Mol Cell Endocrinol 38: 53-60, 1984.

  • Purvis K, Rui H, Attramadal A. Current approaches to research on prostatic function and pathology. Eur Surg Res 16, Suppl. 2: 88-101, 1984.

  • Rui H, Mevag B, Purvis K. Two-dimensional electrophoresis of proteins in various fractions of the human split-ejacu­late. Int J Androl 7: 509-520, 1984.

  • Rui H, Gerhardt P, Mevag B, Thomassen Y, Purvis K. Seminal plasma characteristics during frequent ejaculation. Int J Androl 7: 119-128, 1984.

  • Gerhardt P, Mevag B, Rui H, Tveter KJ, Purvis K. Two-dimensio­nal electrophoresis of proteins from different lobes of the rat prostate and seminal vesicle. The Prostate, 7: 321-326, 1985.

  • Purvis P, Morkas L, Rui H, Attramadal A. Oestrogen receptors in stromal and epithelial fractions of the rat ventral prostate. Arch Androl 15: 143-151, 1985.

  • Rui H, Haug E, Thomassen Y, Purvis K. Short-term effects of prolactin on prostatic function in rats with lisuride-induced hypoprolactinemia. J Reprod Fertil 75: 421-432, 1985.

  • Rui H, Gordeladze JO, Mevag B, Haug E, Brekke I, Purvis K. Circadian rhythms in accessory sex gland function in the male rat. Urol int 40: 331-336, 1985.

  • Rui H, Torjesen PA, Jacobsen H, Purvis K. Testicular and glandu­lar contributions to the prolactin pool in human semen. Arch Androl 15: 129-136, 1985.

  • Purvis K, Rui H, Gordeladze JO, Attramadal H. Hormonal activat­ion of the adenylyl cyclases of the rat and human prostate gland. The Prostate 8: 11-24, 1986.

  • Rui H, Thomassen Y, Oldereid NB, Purvis K. Accessory sex gland function in normal young (20-25 years) and middle-aged (50-55 years) men. J Androl, 7: 93-99, 1986.

  • Purvis K, Haug E, Thomassen Y, Mevag B, Rui H. Short-term effects of mating on the accessory sex glands of the male rat. J Reprod Fertil, 77: 373-380, 1986

  • Oldereid NB, Thomassen Y, Rui H, Gordeladze JO, Haug E, Purvis K. Effects of oestrogen-induced hyperprolactinaemia on the rat prostate. Andrologia, 18, 516-522,1986.

  • Rui H, Brekke I, Morkas L, Purvis K. Androgen interaction with the polyamine system in the rat prostate. Andrologia, 19: 134-142, 1986.

  • Rui H, Morkas L, Purvis K. Time and temperature related altera­tions in seminal plasma constituents after ejacula­tion. Int J Androl, 9: 195-200, 1986.

  • Rui H, Brekke I, Torjesen PA, Purvis K. Homologous up-regulation of the prolactin receptor in rat prostatic explants. Mol Cell Endocrinol, 46: 53-57, 1986.

  • Purvis K, Rui H, Brekke I, Sunde A. 5a-reductase in the non-secretory cells of rat ventral prostate epithelium. J Steroid Biochem, 25: 1023-1025, 1986.

  • Magnus O, Purvis K, Rui H, Clausen OPF, Abyholm T, Gor­deladze JO. Biochemical correlates of asthenozoospermia: A lesion at the level of sperm adenylyl cyclase. Arch Androl, 17: 165-172, 1986.

  • Purvis K, Magnus O, Morkas L, Abyholm T, Rui H. Ejaculate composition after masturbation and coitus in the human male. Int J Androl, 9: 401-406, 1986.

  • Rui H, Brekke I, Torjesen PA, Purvis K. Further observations on the homologous up-regulation of prolactin receptors in rat prostate. Acta Endocr, 114: 426-432, 1987.

  • Rui H, Purvis K. Prolactin selectively stimulates the ornithine decarboxylase in the lateral lobe of the rat prostate. Mol Cell Endocrinol, 50: 89-97, 1987.

  • Rui H, Nielsen JH, Purvis K, Dolva LO. Thyrotropin-relea­sing­hormone (TRH) in human ejaculate. J Endocrinol, 115: 329-334, 1987.

  • Rui H, Purvis K. Independent control of citrate production and ornithine decarboxylase by prolactin in the lateral lobe of the rat prostate. Mol Cell Endocrinol 52: 91-95, 1987.

  • Rui H and Purvis K. Hormonal control of prostate func­tion. Scand J Urol Nephrol, Suppl 107, 32-38, 1988.

  • Purvis K, Rui H. Seminal plasma markers in the evaluation of pros­tatic disease. Scand J Urol Nephrol, Suppl 107, 46-51, 1988.

  • Purvis K, Attramadal A, Rui H, Abyholm T, Magnus O. Studies of human sperm motility using laser-doppler technique [Studier av human spermiemotilitet ved laser-doppler metodikk]. Tidsskr Nor Laege­foren, 108, 1128-1132, 1988.

  • Gordeladze JO, Rui H, Attramadal A, Tveter K, Gautvik K, Purvis K. Distribution of thyroliberin (TRH) - and 12-O-tetradecanoylphorbol 13-acetate (TPA)-activated adenylyl cyclase in normal and neoplastic tissue with special reference to the prostate. Mol Cell Endocrinol 58, 287-289, 1988.

  • Purvis K, Mevag B, Teige B, Torjesen P, Jakobsen H, Rui H, Attramadal A. Prostatic secretory products as markers of pros­tatic neoplasms. Acta Pathol Microbiol Immunol Scand 96, Suppl. 2, 224-237, 1988.

  • Purvis K, Attramadal A, Rui H, Tollefsrud A, Abyholm T, Magnus O. Sperm motility. Physiology, analytical methods and clinical aspects [Spermiemotilitet. Fysiologi, analysemetoder og kliniske aspekter]. Tidsskr Nor Laegeforen, 108, 1128-1132, 1988.

  • Jakobsen H, Rui H, Hald T, Purvis K. Polyamines and other accessory sex gland secretions in human seminal plasma eight years after vasectomy. J Reprod Fert, 87, 39-45, 1989.

  • Purvis K, Tollefsrud A, Rui H. Stability of sperm charac­teristics in men with disturbances in sperm quality. Int J Androl, 12, 171-178, 1989.

  • Purvis K, Tollefsrud A, Rui H. Correlates of human sperm motility assessed by laser-doppler spectroscopy. Int J Androl 12, 10-16, 1989.

  • Rui H, Purvis K, Gordeladze, JO. Sperm adenylyl cyclase in normal men. Andrologia, 21, 131-135, 1989.

  • Oldereid NB, Rui H, Clausen OPF, Purvis K. Cigarette smoking and human sperm quality assessed by laser-doppler spectro­scopy and DNA flow cytometry. J Reprod Fert 86, 731-736, 1989.

  • Rui H, Oldereid NB, Purvis K. Smoking and sperm quality among men attending the infertility clinic [Royking og sadkvalitet hos menn under infertilitetsutredning]. Tidsskr Nor Laegeforen, 109, 573-575, 1989.

  • Purvis K, Rui H, Scholberg A, Hesla S, Clausen OPF. Application of flow cytometry to studies on the human acrosome. J Androl 11, 361-366, 1990.

  • Oldereid NB, Rui H, Purvis K. Male partners in infertile couples. Personal attitudes and contact with the Norwegian health service. Scand J Soc Med 18, 207-211, 1990.

  • Oldereid NB, Rui H, Purvis K. Infertility studies in men [Menn under infertilitetsutredning]. Tidsskr Nor Laegeforen 111, 1265-8, 1991.

  • Crowe P, Buckley AR, Zorn NE, Rui H. Prolactin stimulates growth-related gene expression in rat liver. Mol Cell Endocrinol, 79, 29-35, 1991.

  • Purvis K, Tollefsrud A, Rui H, Haug E, Norseth J, Viksmoen L, Ose L, Lund H. Short-term effects of treatment with simvastatin on testicular function in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Pharmacol, 42, 61-64, 1992.

  • Oldereid NB, Rui H, Purvis K. Life styles of men in barren couples and their relationship to sperm quality. Int J Fertil 37, 343-349, 1992.

  • Oldereid NB, Rui H, Purvis K. The value of anamnestic information regarding previous genital infection in male fertility investigation. Eur J Obst Gyn Reprod Biol, 47, 207-212, 1992.

  • Rui H, Djeu JY, Evans GA, Kelly PA, Farrar WL. Prolactin receptor triggering: Evidence for rapid tyrosine kinase activation. J Biol Chem, 267, 24076-24081, 1992.

  • Djeu JY, Lui JH, Wei S, Rui H, Pearson CA, Leonard W, Blanchard DK. Function associated with IL2 receptorbeta on human neutrophils. Mechanism of activation of antifungal activity against Candida albicans by IL2. J Immunol, 150, 960-970, 1993.

  • Kirken RA, Rui H, Evans GA, Farrar WL. Characterization of a 116 kDa protein associated with the IL-2 receptor b-subunit. J Biol Chem, 268, 22765-22770, 1993.

  • Rui H, Kirken RA, Farrar WL. Activation of receptor-associated tyrosine kinase JAK2 by prolactin. J. Biol. Chem, 269, 5364-5368, 1994.

  • DaSilva L, Howard OM, Rui H, Kirken RA, Farrar WL. Growth signaling and JAK2 activation mediated by membrane-proximal cytoplasmic regions of prolactin receptors. J Biol Chem, 269, 18267-70, 1994.

  • Kirken RA, Rui H, Malabarba MG, Farrar WL. Identification of the IL-2 receptor-associated tyrosine kinase p116 as novel leukocyte specific Janus kinase. J Biol Chem, 269, 19136-41, 1994.

  • Rui H, Lebrun J-J, Kirken RA, Kelly PA, Farrar WL. JAK2 activation and cell proliferation induced by antibody-mediated prolactin receptor dimerization. Endocrinology, 135, 1299-1306, 1994. [Editorial Comment in: Endocrinology 135, 1289-91, 1994].

  • Oldereid NB, Rui H, Purvis K. Male infertility. Significance of life style and occupation. [Mannlig infertilitet: Betydning av livsstil og yrke]. Tidsskr Nor Laegeforen 114, 3308-11, 1994.

  • Malabarba MG, Kirken RA, Rui H, Koettnitz K, Kawamura M, O''Shea JJ, Kalthoff FS, Farrar WL. Activation of JAK3, but not JAK1, is critical for interleukin-4 (IL4) induced proliferation and requires a membrane-proximal region of IL4 receptor a. J Biol Chem, 270, 9630-9637, 1995.

  • Duhe R, Rui H, Greenwood JD, Garvey K, Farrar WL. Molecular cloning of rat JAK2, a protein tyrosine kinase. Gene, 158, 281-285, 1995.

  • Erwin RA, Kirken RA, Malabarba MG, Farrar WL, Rui H. Prolactin activates RAS via signalling proteins SHC, growth factor receptor bound 2, and son of sevenless. Endocrinology, 136, 3512-3518, 1995.

  • Kirken RA, Rui H, Malabarba MG, Howard OMZ, Kawamura M, O''Shea JJ, Farrar WL. Activation of JAK3, but not JAK1, is critical for IL2-induced proliferation and STAT5 recruitment by a COOH-terminal region of the IL2 receptor b-chain. Cytokine, 7, 689-700, 1995.

  • DaSilva L, Rui H, Erwin RA, Howard OMZ, Kirken RA, Malabarba MG, Hackett RH, Larner AC, Farrar WL. Prolactin recruits STAT1, STAT3 and STAT5 independent of conserved receptor tyrosines Tyr402, Tyr479, Tyr515 and Tyr580. Mol Cell Endocrinol, 117, 131-140, 1996.

  • Malabarba MG, Rui H, Deutsch H, Koettnitz K, Kalthoff FS, Farrar WL, Kirken RA. Interleukin13 mimics interleukin4 induced activation of JAK3 and STAT6 via hetero­dimeri­zation of interleukin-4 receptor-a and interleukin-2 receptor-g. Biochem J, 319; 865-872, 1996.

  • Kirken RA, Malabarba MG, Xu J, Liu X, Farrar WL, Hennighausen L, Larner AC, Grimley PM, Rui H. Prolactin stimulates serine/tyrosine phos­phory­lation and formation of heterocomplexes of multiple Stat5 isoforms in Nb2 lymphocytes. J Biol Chem 272, 14098-15003, 1997.

  • Kirken RA, Malabarba MG, Xu J, Erwin RE, DaSilva L, Liu X, Hennighausen L, Rui H, Farrar WL. Two discrete regions of interleukin-2 (IL2) receptor-b independently mediate IL2 acti­vation of a PD98059/rapamycin/wortmannin-insensitive Stat5a/b serine kinase. J Biol Chem, 272, 15459-15465, 1997.

  • Rui H, Xu J, Dong F, Mehta S, Fang H, Williams J, Grimley PM. Activation of the Jak2-Stat5 signaling path­way in Nb2 lymphoma cells by an anti-apoptotic agent, aurintricarboxylic acid. J Biol Chem, 273, 28-32, 1998.

  • Grimley PM, Fang H, Rui H, Petricoin III EF, Ray S, Dong F, Fields KH, Hu R, Zoon KC, Audet S, Beeler J. Interruption of the interferon-a signal in malignant lymphoma cells distinguishes a critical period of STAT activation prerequisite to growth arrest. Blood, 91; 1-12, 1998.

  • Schaber JD, Fang H, Xu J, Grimley PM, Rui H. Prolactin activates Stat1 but does not antagonize Stat1-mediated growth inhibition by type I interferons human breast cancer cells. Cancer Research, 58; 1914-1919, 1998.

  • Yamashita H, Xu J, Erwin RA, Farrar WL, Kirken RA, Rui H. Differential control of the phosphorylation state of proline-juxtaposed serine residues S725 of Stat5a and S730 of Stat5b in prolactin-sensitive cells. J Biol Chem, 273; 30218-30224, 1998.

  • Yamashita H, Xu J, Erwin RA, Larner AC, Rui H. A lymphoma growth inhibitor blocks some but not all prolactin-stimulated signaling pathways. J Biol Chem, 274; 14699-14705, 1999.

  • Ahonen TJ, Härkönen PL, Laine J, Rui H, Martikainen PM, Nevalainen MT. Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. Endocrinology, 140, 5412-21, 1999.

  • Nevalainen MT, Ahonen TJ, Yamashita H, Chandrashekar V, Bartke A, Grimley PM, Robinson GW, Hennighausen L, Rui H. Epithelial defect in prostates of Stat5a null mice. Lab Invest, 80, 993-1006, 2000.

  • Kirken RA, Erwin RA, Wang L, Rui H, Farrar WL. Functional uncoupling of the Jak3-Stat5 pathway in malignant growth of HTLV-1 transformed human T-cells. Journal of Immunology, 165:5097-104, 2000.

  • Yamashita H, Nevalainen MT, Xu J, LeBaron MJ, Wagner KU, Erwin RA, Harmon G, Hennighausen L, Kirken RA, Rui H. Role of serine phosphorylation of Stat5a in prolactin-stimulated b-casein gene expression. Molecular and Cellular Endocrinology, 183:151-163, 2001.

  • Park S-H, Yamashita H, Rui H, Waxman DJ. Serine phosphorylation of growth hormone-activated STAT5a and STAT5b: Impact on STAT5 transcriptional activity. Molecular Endocrinology, 15:2157-71, 2001.

  • Ahonen TJ, Harkonen P, Rui H, Nevalainen MT. Prolactin signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro. Endocrinology, 143:228-238, 2002.

  • Xie J, LeBaron MJ, Nevalainen MT, Rui H. Role of tyrosine kinase Jak2 in prolactin-induced differentiation and growth of mammary epithelial cells. Journal of Biological Chemistry, 277, 14020-14030, 2002.

  • Nevalainen MT, Xie J, Bubendorf L, Wagner K-U, Rui H. Basal activation of transcription factor Stat5 in non-pregnant mouse and human breast epithelium. Molecular Endocrinology, 16, 1108-1124, 2002.

  • Boer A-K, Drayer AL, Rui H, Vellenga E. Prostaglandin-E2 enhances EPO-mediated STAT5 transcriptional activity by serine phosphorylation of CREB. Blood, 100, 476-73, 2002.

  • Nagy ZS, Erwin-Cohen RA, Wang L, Aradi J, Monia B, Stepkowski SM, Rui H, Kirken RA. Interleukin-2 family cytokines stimulate phosphorylation of the Pro-Ser-Pro-motif of Stat5 transcription factors in human T cells: Resistance to suppression of multiple serine kinase pathways. Journal of Leukocyte Biology, 72, 819-28, 2002.

  • Benitah SA, Valeron PF, Rui H, Lacal JC. STAT5a Activation Mediates the Epithelial to Mesenchymal Transition Induced by Oncogenic RhoA. Mol Biol Cell, 14: 40-53, 2003.

  • Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K, Rui H, Nevalainen MT. Inhibition of Transcription Factor Stat5 Induces Cell Death of Human Prostate Cancer Cells. J Biol Chem, 278: 27287-92, 2003.

  • Uddin S, Lekmine F, Sassano A, Rui H, Fish EN, Platanias LC. Role of Stat5 in Type I interferon-signaling and transcriptional regulation. Biochem Biophys Res Commun, 308: 325-30, 2003.

  • Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J, Sauter G, Rui H. Signal Transducer and Activator of Transcription-5 activation and breast cancer prognosis. Journal of Clinical Oncology, 22, 2053-2060, 2004.

  • Wagner K-U, Krempler A, Triplett AA, Qi Y, George NM, Zhu J, Rui H. Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. Molecular Cell Biology, 24, 5510-5520, 2004.

  • Krempler A, Qi Y, Triplett AA, Zhu J, Rui H, Wagner K-U. Generation of a conditional knockout allele for the Janus Kinase 2 (Jak2) gene in mice. Genesis, 40, 52-57, 2004.

  • Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H. Transcription factor Stat5 stimulates homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene, 24, 746-760, 2005.

  • LeBaron MJ, Xie J, Rui H. Evaluation of a genome-wide Chromatin library of Stat5 binding sites in human breast cancer. Molecular Cancer, 4:6, 2005; doi: 10.1186/1476-4598-4-6 (10 pages).

  • LeBaron MJ, Crismon HR, Utama FE, Neilson LM, Sultan AS, Johnson KJ, Andersson EC, Rui H. Ultrahigh density microarrays of solid samples. Nature Methods 2, 511-513, 2005. Comment in: Nature Methods. 2005 Jul;2(7):492-3.

  • Finkel TH, Selliah N, Zhang M, DeSimone D, Brunner M, Ittenbach RF, Rui H, Cron R. The ³c-Cytokine regulated transcription factor, Stat5, increases HIV-1 production in primary CD4 T-cells. Virology, 344,283-91,2006

  • Utama FE, LeBaron MJ, Neilson LM, Sultan AS, Parlow AF, Wagner K-W, Rui H. Human prolactin receptors are insensitive to mouse prolactin: Implications for xenotransplant modeling of human breast cancer in mice. Journal of Endocrinology, 188,589-601,2006.

  • Nagy ZS, Erwin-Cohen RA, Wang L, Aradi J, Monia B, Stepkowski SM, Rui H, and Kirken RA. Interleukin-2 family cytokines, but not T cell receptor engagement, stimulate phosphorylation of the Pro-Ser-Pro-motif of Stat5 transcription factors in human T cells: Resistance to suppression of multiple serine kinase pathways. J Immunol, 2006, in press.

  • Sotgia F, Rui H, Pestell RP, Lisanti MP. Caveolin-1, Mammary Stem Cells, and Estrogen-Dependent Breast Cancers. Cancer Research, 2006, in press.

  • Williams TM, Sotgia F, Lee H, Hassan G, Di Vizio D, Bonuccelli G, Capozza F, Mercier I, Rui H, Pestell RP, Lisanti MP. Stromal and Epithelial Caveolin-1 both Confer a Protective Effect Against Mammary Hyperplasia and Tumorigenesis: Caveolin-1 antagonizes Cyclin D1 function in Mammary Epithelial Cells. Am J. Pathol 169, 2006, in press.

  • Dalmizrak O, Wu A, Chen J, Sun H, Utama FE, Zambelli D, Tran TH, Rui H, Baserga R. The Insulin receptor substrate-1 regulates the transformed phenotype of BT-20 human breast cancer cells. Cancer Research, 67, 2124-30, 2007.

  • Neilson LM, Zhu J, Xie J, Malabarba MG, Sakamoto K, Wagner K-U, Kirken RA, Rui H. Coactivation of Jak1 Positively Modulates Prolactin-Jak2 Signaling in Breast Cancer: Recruitment of ERK and Stat3 and Enhancement of Akt and Stat5a/b Pathways. Molecular Endocrinology, 21, 2218-2232, 2007.

  • Plotnikov A, Li Y, Tran TH, Tang W, Palazzo JP, Rui H, and Fuchs SY. Oncogene-mediated inhibition of glycogen synthase kinase 3² impairs degradation of prolactin receptor. Cancer Research, 2008, in press.

  • Lindsay J, Jiao X, Sakamaki T, Casimiro MC, Shirley LA, Tran TH , Ju X, Liu M, Li Z, Wang C, Katiyar S, Rao M, Allen KG, Glazer RI, Ge C, Stanley P, Lisanti MP, Rui H and Pestell RG. ErbB2 induces Notch1 activity and function in breast cancer cells. Clinical and Translational Science, 2008, in press.

  • **** Peer-reviewed Reviews ****

  • Rui H, Purvis K. Hormonal control of prostate function. Scand J Urol Nephrol Suppl, 107, 32-8, 1988.

  • Purvis K, Attramadal A, Rui H. Secretory function of the prostate gland. Scand J Urol Nephrol Suppl, 107, 46-51, 1988.Rui H, Purvis K. Hormonal control of prostate function. Scand J Urol Nephrol Suppl, 107, 32-8, 1988.

  • Kirken RA, Rui H, Howard OMZ, Farrar WL. Involvement of JAK family tyrosine kinases in hematopoietin receptor signal transduction. Prog Growth Factor Res, 5, 195-211, 1994.

  • Murphy WJ, Rui H, Longo DL. Effects of neuroendocrine hormones on immune development and function. Life Sciences, 57, 1-14, 1995.

  • Grimley PM, Dong F, Rui H. Stat5a and Stat5b: Fraternal twins of signal transduction and transcriptional activation. Cytokine & Growth Factor Reviews, 10, 131-157, 1999.

  • Rui H, LeBaron MJ. Creating tissue microarrays by cutting edge matrix assembly. Expert Review of Medical Devices, 2,673-680, 2005 (doi: 10.1586/17434440.2.6.673).

  • Wagner K, Rui H. Jak2/Stat5 Signaling in Mammogenesis, Breast Cancer Initiation and Progression. Mammary Gland Biology Neoplasia, 2008, Jan 29, (doi: 10.1007/s10911-008-9062-z).

  • **** Books, book chapters, thesis, and publications in other journals ****

  • Rui H, Gordeladze JO, Haug E, Purvis K. Accessory sex gland parameters in the male rat. Circadian rhythms and effects of prolactin withdrawal. In: Advances in Urological Oncology and Endocrinology, Proceedings of the 3rd Congress of the European Society for Urological Oncology and Endocrinology. Bracci U and Di Silverio F (eds), Acta Medica, edizioni e Congressi s.r.l., Roma, pp. 53-62, 1984.

  • Purvis K, Rui H, Tveter KJ, Attramadal A, Gordeladze JO. Peptide activation of the membrane-bound adenylyl cyclase of isolated rat and human prostatic cells. In: Advances in Urologi­cal Oncology and Endocrinology, Proceedings of the 3rd Congress of the European Society for Urological Oncology and Endocrino­logy. Bracci U and Di Silverio F (eds), Acta Medica, edizioni e Congressi s.r.l., Roma, pp. 175-184, 1984.

  • Rui H. Effects and mechanisms of action of prolactin on the prostate. Studies based on the rat. Thesis, University of Oslo School of Medicine, 1987. ISBN-82-90252-23-4.

  • Rui H. High affinity calmodulin-dependent isoforms of testicular cyclic nucleotide phosphodiesterase. Methods in Enzymology, 159, 675-685, 1988.

  • Evans GA, Rui H, Farrar WL. Methods for the identification of intracellular mediators of the actions of cytokines: Identifying proteins involved in Kinase signaling pathways. In: Methods in Neurosciences, Vol 16. E. Souza (ed), Academic Press, pp 49-66, 1993.

  • Rui H, Kirken RA, Duhe RJ, Howard OMZ, Evans GA, Farrar WL. Lymphokine-induced signal transduction. In: Immunopharmacology of Allergic Diseases. Eds: R.G. Townley and D.K. Agrawal. Marcel Dekker, Inc, New York, 1996, pp. 29-77.

  • Rui H. Prolactin. In: Oppenheim and Feldmann Cytokine Reference. Academic Press, London. pp 267- 284, 2000.

  • Rui H, Nevalainen MT. Prolactin. In: Cytokine Handbook, 4th edition, Editors Angus Thomson and Michael T Lotze. Elsevier Science Ltd, London, pp 113-146, 2003.

  • **** Popular Scientific Articles ****

  • Purvis K, Rui H, Attramadal A. Prostata - mannens forbannelse. [Prostate - the male curse]. Supplement to Aftenposten, Norways largest newspaper; A-Magasinet, nr.9: 28-32, 1986.

  • Rui H, Willey S. Early stage of breast cancer: Science, Surgery and Pathology. Georgetown Medicine, pp. 29-32, Spring 2005.

Individual Expertise profile of Hallgeir Rui, M.D., Ph.D., Copyright © Hallgeir Rui, M.D., Ph.D..
Last Updated by Hallgeir Rui, M.D., Ph.D. : Wednesday, October 14, 2009 1:12:48 PM



Maintained by Jerome Buescher
Copyright © Thomas Jefferson University. All Rights Reserved.

 Printable Version

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement.
Thomas Jefferson University